Dosage-form words can hide a more basic question: which medicine is this? Hims 3-in-1 Hard Mints identifies the 3-in-1 chew listing sildenafil, tadalafil and vitamin B12. Although this publication focuses on formulations, the review also follows the product's cost and evidence because a liquid, chew or tablet description alone cannot establish equivalence, benefit or suitability.
The exact product
The distinguishing formulation issue is two ED drugs plus a vitamin, rather than three ED drugs. Keep three fields separate: active ingredients, physical preparation and prescribed administration. Chewable, sublingual and swallowed are not interchangeable instructions. If a product page and safety document use different words, ask the dispensing pharmacist to identify the actual preparation. This review does not infer mixing, holding, chewing or swallowing directions from packaging or from another seller's product.
| Detail | Record |
|---|---|
| Provider | Hims |
| Listed active ingredients | Sildenafil + tadalafil + vitamin B12 |
| Dosage form | Compounded mint-flavored chew |
| Regulatory distinction | Compounded preparation; the finished product is not FDA-approved. |
| Source basis | Hims: current ED treatment catalog · Hims: Hard Mints formulation safety library · Hims: Hard Mints chewable ED medicines |
Price, supply and payment
The public price record is From $30/month in the ED catalog. Compare that figure only after establishing the exact formulation and supplied quantity. A unit can mean a tablet, chew, gummy, shot or allocated dose, and those words do not establish identical clinical exposure. Where quantity or billing period is missing, a cost-per-treatment calculation remains unsupported. Ask for the pharmacy label and complete invoice fields rather than treating package appearance as a measure of supply.
| Detail | Record |
|---|---|
| Current catalog headline | From $30/month |
| Separate chewable-page offer | Selected sildenafil/tadalafil mints from $6/use |
| Price limitation | The two headlines do not establish a five-chew plan |
| Name limitation | Other Hard Mints formulations have different active ingredients |
What the research can support
Formulation changes can limit how evidence transfers. The source context here is ingredient and regimen research; Hims user surveys are not trials of this exact chew, leaving the matching quantity, strengths and upfront payment unanswered. A shared active ingredient does not prove matched absorption, timing, stability or outcomes across preparations. Research on an intranasal, swallowed or separately dosed medicine cannot automatically validate a fixed sublingual or compounded product. The finished prescription needs evidence appropriate to the claim being made.
| Detail | Record |
|---|---|
| Evidence boundary | ingredient and regimen research; Hims user surveys are not trials of this exact chew |
| Not established here | the matching quantity, strengths and upfront payment |
| Clinical and regulatory references | Cui et al. (2015): daily tadalafil with as-needed sildenafil · DailyMed: Tadalafil prescribing information, including section 5.11 · FDA: Compounding and the FDA — questions and answers · MedlinePlus: Sildenafil · MedlinePlus: Tadalafil |
Safety questions for the prescriber
A different physical format does not remove medication interactions. The clinician needs to know about nitrates, nitrites, riociguat, other ED products and blood-pressure treatment, along with relevant health conditions. Do not recreate Hims 3-in-1 Hard Mints by combining or manipulating separate medicines. A pharmacist should clarify the supplied label, storage and handling; personal suitability and any treatment change need the prescribing team's involvement.
| Detail | Record |
|---|---|
| Multiple PDE5 inhibitors | Standard tadalafil labeling advises against combining PDE5 inhibitors; individualized rationale and monitoring are needed. |
| Added nutrients | Review actual amounts and duplicate supplements; nutrient inclusion does not prove improved ED efficacy. |
Availability and the actual prescription
The formulation record has this access limit: Public product listing; individual eligibility and current prescription require confirmation. A safety entry demonstrates documentation, not necessarily a currently supplied product. When an offer changes, the preparation, pharmacy or instructions may also change. Confirm all three instead of assuming a familiar brand name preserves the old directions. Public text cannot verify the exact medicine that would be dispensed to an individual account.
Refills, changes and cancellation
Keep the supplied label available when asking about response or tolerability. Report the exact product and how its prescribed instructions were followed; do not improvise a different route to seek faster effects. A focused question is “Why does this prescription combine both PDE5 inhibitors, and what role does B12 serve?” If the clinician changes the formulation, ask which instructions and storage requirements now apply and confirm that the next shipment contains the intended preparation.
| Detail | Record |
|---|---|
| Next charge | The next order date is the charge/processing date; a first refill can be scheduled early. |
| Cancellation notice | At least 48 hours before the next order, according to support guidance. |
| Already processing | Ending a subscription does not cancel an order already processing or shipped. |
| Refund boundary | No refund guaranteed after pharmacy processing. |
| Policy sources | Hims Support: canceling a subscription · Hims Support: refund policy · Hims Support: when billing occurs |
Compare named products
The comparison links are chosen to expose meaningful formulation differences. Read the complete active list before deciding that two chews, two tablets or two liquids are alike. Conversely, a different package does not prove a different clinical benefit. Consider ingredient, preparation, schedule and evidence separately so that a preference about administration can be discussed without becoming an unsupported equivalence claim.
Questions to keep with the offer
No sample of Hims 3-in-1 Hard Mints was examined for this review. We did not measure concentration, dissolution, stability or patient outcomes, and public descriptions do not substitute for those tests. The source record is useful for identifying questions about a finished prescription, not for compounding instructions or dose conversion. The pharmacy and prescriber must resolve the actual label and use directions.
| Detail | Record |
|---|---|
| Ask about this formula | Why does this prescription combine both PDE5 inhibitors, and what role does B12 serve? |
| Ask about the payment | What are the exact quantity, total due now, renewal amount and notice deadline? |
| Ask about a change | Who confirms the medical instructions, pharmacy order and next account charge? |
When to get urgent help
An erection lasting more than four hours or chest pain requires emergency care. Tell the treating clinician what was taken and when.
Sudden hearing or vision loss needs prompt medical attention. Do not wait for an ordinary account-support reply.
Source records
These records have different purposes. A provider page documents its public wording; it does not independently verify a supplied product, a patient result or the service behind the claim.
- Hims: current ED treatment catalogProvider catalog; individual named offers and starting prices · Checked 2026-10-07
- Hims: Hard Mints formulation safety libraryProvider formulation document; includes options not confirmed in the main catalog · Checked 2026-10-07
- Hims Support: canceling a subscriptionProvider policy; 48-hour notice and orders already processing · Checked 2026-10-07
- Hims Support: refund policyProvider policy; no guaranteed refund after pharmacy processing · Checked 2026-10-07
- Hims Support: when billing occursProvider policy; next order date, charge timing, and subscription intervals · Checked 2026-10-07
- Hims Support: changing the next order dateProvider support; refill rescheduling differs from cancellation · Checked 2026-10-07
- Cui et al. (2015): daily tadalafil with as-needed sildenafilPrimary clinical study; 180 patients, specific regimen, abstract reviewed via NCBI · Checked 2026-10-07
- Hims: Hard Mints chewable ED medicinesProvider source; compounded formulations and advertised starting prices · Checked 2026-10-07
- DailyMed: Tadalafil prescribing information, including section 5.11Prescribing label; not evidence for the 4Play combination · Checked 2026-10-07
- FDA: Compounding and the FDA — questions and answersGovernment guidance on compounded medications · Checked 2026-10-07
- MedlinePlus: SildenafilDrug information; standard sildenafil products · Checked 2026-10-07
- MedlinePlus: TadalafilDrug information; standard tadalafil products · Checked 2026-10-07